Citigroup
UNCY icon

Citigroup’s Unicycive Therapeutics UNCY Stock Holding History

Citigroup’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$857K Buy
182,654
+182,653
+18,265,300% +$1.35M ﹤0.01% 3561
2026
Q1 		$7 Sell
1
-227
-100% -$1.49K ﹤0.01% 5761
2025
Q4 		$1.32K Sell
228
-6,464
-97% -$34.5K ﹤0.01% 5515
2025
Q3 		$29.2K Buy
+6,692
New +$29.2K ﹤0.01% 4674
2025
Q1 		– Sell
-59
Closed -$466 – 5979
2024
Q4 		$466 Buy
+59
New +$327 ﹤0.01% 5629

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Citigroup's UNCY Position: Q2 2026 in Review

Citigroup increased its Unicycive Therapeutics (UNCY) stake by 18,265,300% in Q2 2026, buying an estimated $1.35M and bringing the position to 182,654 shares worth $857K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Citigroup first reported a position in UNCY in Q4 2024 and has held it in 5 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Citigroup held 182,654 shares of Unicycive Therapeutics worth $857K as of Q2 2026.
  • Citigroup bought 182,653 Unicycive Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Unicycive Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3561 holding.
  • Citigroup first reported a position in Unicycive Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.